Page last updated: 2024-11-10

mannomustine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mannomustine: Nitrogen mustard derivative alkylating agent used as antineoplastic. It causes severe bone marrow depression and is a powerful vesicant. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3033867
CHEMBL ID460283
CHEBI ID135296
SCHEMBL ID8195
MeSH IDM0013000

Synonyms (42)

Synonym
576-68-1
1,6-bis[(2-chloroethyl)amino]-1,6-dideoxy-d-mannitol
1,6-bis((beta-chloroethyl)amino)-1,6-dideoxy-d-mannitol
mannomustinum [inn-latin]
mannomustine [inn:ban:dcf]
manomustina [inn-spanish]
mannit-lost [german]
mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-, d-
mannit-mustard [german]
ccris 370
einecs 209-404-3
1,6-bis(chloroethylamino)-1,6-bis-deoxy-d-mannitol
bcm (cytostatic)
1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-d-mannitol
d-mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-
1,6-bis(chloroethylamino)-1,6-dideoxy-d-mannite
mannomustine hydrochloride
nsc-9698
mannitol mustard dihydrochloride
mannomustine dihydrochloride
mannitol mustard
degranol chinoin
mannomustine
mannitol nitrogen mustard
CHEBI:135296
CHEMBL460283
(2r,3r,4r,5r)-1,6-bis(2-chloroethylamino)hexane-2,3,4,5-tetrol
manomustina
e60vwa40d2 ,
mannit-lost
mannit-mustard
mannomustinum
nsc 9698 [as hydrochloride]
unii-e60vwa40d2
mannomustine [inn]
nsc-9698 free base
SCHEMBL8195
3-ethyl-piperazine-1-carboxylicacidtert-butylester
DTXSID9020798
d-mannitol, 1,6-bis[(2-chloroethyl)amino]-1,6-dideoxy-
1,6-bis-[2-chloroethylamino]-1,6-didesoxy-d-mannitol
Q27276910
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino alcoholAn alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409943Inhibition of human recombinant MAOB by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (183)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990181 (98.91)18.7374
1990's0 (0.00)18.2507
2000's1 (0.55)29.6817
2010's1 (0.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.01 (24.57)
Research Supply Index5.31 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.50%)5.53%
Reviews8 (4.00%)6.00%
Case Studies2 (1.00%)4.05%
Observational0 (0.00%)0.25%
Other189 (94.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]